Cytokines: Triggers of Clinical Thrombotic Disease

Jan W ten Cate; Tom van der Poll; Marcel Levi; Hugo ten Cate; Sander J H van Deventer

doi:10.1055/s-0038-1657562

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1997; 78(01): 415-419
DOI: 10.1055/s-0038-1657562

Cytokines and thrombosis

Schattauer GmbH Stuttgart

Cytokines: Triggers of Clinical Thrombotic Disease

Jan W ten Cate

¹Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, Amsterdam, the Netherlands

,

Tom van der Poll

²Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

,

Marcel Levi

¹Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, Amsterdam, the Netherlands

,

Hugo ten Cate

¹Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, Amsterdam, the Netherlands

²Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

,

Sander J H van Deventer

²Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

› Institutsangaben

Abstract

als PDF herunterladen

PDF (1045 kb)

Referenzen

References
1 Levi M, ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
2 Van der Poll T, Lowry SF. Biological responses to endotoxin in humans. In: Tellado JM, Forse RA, Solomkin JS. (eds) Modulation of the Inflammatory Response in Severe Sepsis. Karger AG; Basel: 1995: 18-32
3 Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack Van Schijndel RIM, Felt-Bersma RTM, Thijs LG, Hack CE. Quantification of plasma factor XIIa-Cl-inhibitor complexes and kallikrein-Cl-inhibitor complexes in sepsis. Blood 1988; 72: 1841-1848
4 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infections related to unfavourable prognosis. Thromb Haemostas 1983; 49: 5-7
5 Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. B J Haematol 1990; 75: 99-105
6 Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, and α₂-antiplasmin, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-278
7 Van Deventer SJH, Büller HR, Ten Cate JW, Aarden LA, Hack CE, Stuik A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76: 2520-2526
8 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
9 De Boer JP, Creasy AA, Chang A, Roem D, Brouwer MC, Eerenberg AJM, Hack CE, Taylor jr FB. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose ofEscherichia coli. . CircShoc 1993; 39: 59-67
10 Taylor Jr FB. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 1994; 388: 175-194
11 Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor Jr FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992; 140: 897-906
12 Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB, Colman RW. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 1993; 91: 61-68
13 Levi M, Ten Cate H, Bauer KA, Van der Poll T, Edgington TS, Büller HR, Van Deventer SJH, Hack CE, Ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
14 Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS, Lethal E. coliis prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134
15 Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality fromEscherichia coliseptic shock. J Clin Invest 1993; 91: 2850-2860
16 Biemond BJ, ten Cate H, Levi M, Soule HR, Morris LD, Foster DL, Bogowitz CA, van der Poll T, Büller HR, ten Cate JW. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995; 73: 223-230
17 Taylor Jr FB, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT. DEGR-factor Xa blocks disseminated intravscular coagulation initiated byEscherichia coliwithout preventin shock or organ damage. Blood 1991; 78: 364-368
18 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
19 Taylor Jr FB, Chang A, Esmon T, D’Angelo A, Vigano-D’Angelo D, Blick KE. Protein C prevents the coagulopathic and lethal effects ofEscherichia coliinfusion the baboon. J Clin Invest 1987; 9: 918-925
20 Taylor Jr FB, Chang A, Ferrell G, Mather T, Blick K, Esmon CT. C4b-binding protein exacerbates die host response toEscherichia coli . Blood 1991; 78: 357-363
21 Lowry SF, Calvano SE, van der Poll T. Measurement of inflammatory mediators in clinical sepsis. In Sibbald WJ, Vincent JL. (eds) Clinical Trials for the Treatment of Sepsis. Springer-Verlag. 1995: 86-105
22 Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino jr MA, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-153
23 Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KR, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowiy SF, Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-1633
24 van deer Poll T, Levi M, Van Deventer SJH, Ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, Ten Cate JJW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451
25 van der Poll T, Levi M, Hack CE, Ten Cate H, Van Deventer SJH, Eerenberg AJM, De Groot ER, Jansen J, Gallati H, Büller HR, Ten Cate JW, Aarden LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
26 van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJH. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180: 1985-1988
27 Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664
28 Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor Jr FB, Murray CK, Peer GT, Emerson jr TE, Passey B, Kuo GC. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 1990; 30: 279-292
29 Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-552
30 Fischer E, Marano MA, Van Zee K, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL. Interleukin-1 receptor blockade improves survival and hemodynamic performance inEscherichia coli septic shock but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557
31 Moore KW, O’Gana A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-190
32 Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208
33 Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gerard C, Delvaux A, de Groote D, Abramowicz D, Velu T, Goldman M. IL- 10 controls IFN-γ and TNF production during experimental endotoxemia. Eur J Immunol 1994; 24: 1167-11671
34 Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin-6-deficient mice. J Exp Med 1994; 180: 1243-1250
35 van der Poll T, Büller HR, Ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627
36 van der Poll T, Levi M, Büller HR, Van Deventer SJH, De Boer JP, Hack CE, Ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732
37 van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, Buurman WA, Hack CE, ten Cate JW, Agosti JM, Lowry SF. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. in press
38 Biemond BJ, Levi M, ten Cate H, van der Poll T, Büller HR, Hack CE, ten Cate JW. Plasminogen activator and PAI-1 release during experimental endotoxemia in chimpanzees: effects of various interventions in die cytokine and coagulation cascades. Clin Sci 1995; 88: 587-594
39 Jansen PM, Boermeester MA, Fischer E, de Jong IW, van derPoll T, Moldawer LL, Hack CE, Lowry SF. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, to neutrophil degranulation and the release of sPLA₂in sepsis Studies in nonhuman primates following interleukin-lα administration and during lethal bacteremia. Blood 1995; 86: 1027-1034
40 Boermeester MA, van LeeuwenPAM, Coyle SM, Houdijk AJP, Eerenberg AM, Wolbink GJ, Pribble JP, Stiles DM, Wesdorp RIC, Hack CE, Lowry SF. Inlerieukin-1 receptor blockade in patients with sepsis syndrome: evidence that interleukin-1 contributes to the release of interleukin-6, elastase and phospholipase A₂and the activation of the complement, coagulation and fibrinolytic systems. Arch Surg 1995; 130: 739-748
41 Stouthard JML, Levi M, Hack CE, Veenhof CHN, Romijn JA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemostas 1996; 76: 738-742
42 Pradier O, Gérard C, Delvaux A, Lybin M, Abramowicz D, Capel P, Velu T, Goldman M. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 1993; 23: 2700-2704
43 van derPoll T, Jansen PM, Montegut WJ, Braxton CC, Calvano SE, Stackpole SA, Smith SM, Swanson SW, Hack CE, Lowry SF, Moldawer LL. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. in press
44 Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJH. Interleukin 10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. in press